Adding Sugemalimab to CAPOX Improves Outcomes in Gastric/GEJ

Adding sugemalimab to CAPOX improved outcomes in patients with previously untreated, advanced gastric/GEJ adenocarcinoma in a phase 3 trial.

Related Keywords

China , Beijing , Xiaotian Zhang , Cstone Pharmaceuticals , Beijing Cancer Hospital ,